Monte Rosa reports positive early results for new heart inflammation drug

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102 in 108 obese subjects with elevated cardiovascular risk randomized to once-daily 5 mg, 20 mg, or 40 mg doses or placebo for four weeks, with four weeks of follow-up.

According to the company, MRT-8102 produced robust and sustained NEK7 degradation with a median reduction of approximately 80 to 90% across doses. It reduced multiple plaque-associated damage-associated molecular patterns and cytokines toward healthy volunteer levels. Median reductions reported included calprotectin 56%, S100A12 46%, SAA 51%, HMGB1 40% and IL-1β 37% in subjects with top-quartile baseline values.

Systemic biomarkers and thrombogenic factors were also lowered, with median IL-6 and hsCRP reductions of 54% and 85%, fibrinogen reduced by 28%, and lipoprotein(a) reduced by 24% without increases in LDL-C or triglycerides.

MRT-8102 was well tolerated with no serious adverse events and treatment-emergent adverse event rates similar to placebo (33% versus 30%) and no evidence of increased infection risk.

The company expects to initiate Phase 2 studies GFORCE-2 in H1 2027, GEMINI-1 in Q4 2026 or Q1 2027, and GALAXY-1 in H1 2027.

Source: https://www.globenewswire.com/news-release/2026/10/01/3372740/0/en/monte-rosa-therapeutics-announces-positive-results-for-mrt-8102-in-gforce-1-phase-1-study-showing-normalization-of-key-pathogenic-drivers-of-ascvd-in-subjects-with-elevated-cvd-ris.html

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE